Q-omics provides the consensus-scored SUGCT profile across patient tissues and cancer cell-line models. SUGCT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUGCT is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SUGCT RNA expression shows 18,084 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where SUGCT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUGCT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUGCT survival associations across molecular data types. SUGCT RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUGCT RNA expression–survival associations across cancer types. High SUGCT expression shows unfavorable associations in MESO, BLCA and BRCA, but favorable associations in KIRC, UVM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUGCT RNA expression.
This table summarizes SUGCT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUGCT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUGCT shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, LUAD, LUSC and BRCA. The HNSC box plot shows higher SUGCT RNA expression in tumor versus normal tissue (log2 FC = +1.893, t-test p < 0.001).
This table shows molecular features associated with SUGCT in patient tissues and cancer cell lines. In patient samples, SUGCT shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUGCT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
